Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
about
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphomaExploiting natural anti-tumor immunity for metastatic renal cell carcinoma.Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trialIn vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma.Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survivalCarbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes.Pretreatment with interferon-alpha2a modulates perioperative immunodysfunction in patients with renal cell carcinoma.
P2860
Q34402325-7278D0DA-D0A3-462B-B9D3-A90E65598C6AQ35717862-D8D58FDF-7C16-4EF4-A9B4-ABEBCC117872Q35887319-3CC391B7-9821-4801-84EA-DD92962A56BAQ36241273-4FBF7F0B-C55D-4DAB-BC1C-0A950013433CQ36611853-AB77BC9A-C724-4423-BC6A-5C02E75B3277Q36613642-400BE751-2487-4B21-8C5A-FC7657F054F1Q36694623-2C26A39F-CE91-48C7-8B58-C6BBBD0F543AQ37222476-544502CE-A819-4419-B78D-66083F3EFB33Q39396204-7870E5AF-A38B-4B87-87D5-F36860519A9FQ39604051-8DE70EE2-C229-4640-BE1B-0CFD9FF13491Q40723187-7E14F312-822A-472A-A035-DEC80D26D3A4Q45217743-CE2338D1-7DE2-4CA1-82C8-AD00CBE1A431Q46758739-AC8C69AE-34D5-4F78-A8FD-E06A5F719728
P2860
Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Intratumoural and peripheral b ...... jective response and survival.
@ast
Intratumoural and peripheral b ...... jective response and survival.
@en
type
label
Intratumoural and peripheral b ...... jective response and survival.
@ast
Intratumoural and peripheral b ...... jective response and survival.
@en
prefLabel
Intratumoural and peripheral b ...... jective response and survival.
@ast
Intratumoural and peripheral b ...... jective response and survival.
@en
P2093
P2860
P356
P1476
Intratumoural and peripheral b ...... jective response and survival.
@en
P2093
H Von Der Maase
J J Jensen
K M Bennedsgaard
N Marcussen
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600437
P407
P577
2002-07-01T00:00:00Z